Financial PositionArdelyx maintained a strong cash position of ~$214M, providing flexibility for continued commercial investment and pipeline opportunities.
Product DifferentiationIBSRELA offers unique differentiation by functioning as a sodium/hydrogen exchanger 3 inhibitor, impacting abdominal pain reduction and addressing constipation, pain, and associated bloating.
Sales GrowthFocusing on growth strategy with reported year-over-year double-digit growth across both oral tablet products, IBSRELA and XPHOZAH.